Ultragenyx Pharmaceutical Inc.

RARE · Nasdaq · SIC 2834: Pharmaceutical Preparations
266
SEC Filings

Business Summary

PART I Item 1. Bus iness Overview We are a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. We have built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease. We were founded in April 2010 by our President and Chief Exe...

Next Earnings

Q2 FY2026 — expected 2026-09-13

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionRAREdiscussed_in_filing Cybersecurity
topic_mentionRAREdiscussed_in_filing Cybersecurity
topic_mentionRAREdiscussed_in_filing Healthcare & Bio
topic_mentionRAREdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-182025-12-310001193125-26-057329EDGAR85K words
2025-02-192024-12-310000950170-25-023312EDGAR—
2024-02-212023-12-310000950170-24-017879EDGAR—
2023-02-172022-12-310000950170-23-003096EDGAR—
2022-02-152021-12-310000950170-22-001284EDGAR—
2021-02-122020-12-310001564590-21-005610EDGAR—
2020-02-142019-12-310001564590-20-004667EDGAR—
2019-02-202018-12-310001564590-19-003324EDGAR—
2018-02-212017-12-310001564590-18-002535EDGAR—
2017-02-172016-12-310001564590-17-001714EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-052025-09-300001193125-25-265126EDGAR55K words
2025-08-062025-06-300000950170-25-103290EDGAR—
2025-05-072025-03-310000950170-25-064726EDGAR—
2024-11-062024-09-300000950170-24-121679EDGAR—
2024-08-022024-06-300000950170-24-089488EDGAR—
2024-05-032024-03-310000950170-24-052346EDGAR—
2023-11-032023-09-300000950170-23-058427EDGAR—
2023-08-042023-06-300000950170-23-038173EDGAR—
2023-05-052023-03-310000950170-23-018017EDGAR—
2022-11-032022-09-300000950170-22-021366EDGAR—
2022-07-292022-06-300000950170-22-013411EDGAR—
2022-05-062022-03-310000950170-22-007940EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-04-020001193125-26-139084EDGAR1K words
2026-03-300001193125-26-130498EDGAR—
2026-03-120001193125-26-103167EDGAR—
2026-02-230001193125-26-062568EDGAR—
2026-02-120001193125-26-048738EDGAR—
2026-02-030001193125-26-034474EDGAR—
2026-01-300001193125-26-030590EDGAR—
2026-01-120001193125-26-009791EDGAR—
2025-12-300001193125-25-337099EDGAR—
2025-12-290001193125-25-332422EDGAR—

266 total filings indexed. 234 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001515673
TickerRARE
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: f0463bf9b8b6ea333c1a511bce536cd74975117ba1ce779dc627baa1f56925f1
parent: adcfebff812624c3fa37cf55dcb737c8159997ff71a220cec82e4f96d799080e
content hash: a65bb8f49b9eb2d39240c90c5400d253f63956a429d5723bfa81727ba13349ee
signed: 2026-04-13T04:47:07.378Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf